It’s not a cure. But this latest gain for targeted cancer therapy could open new treatment possibilities.
This undated photo provided by Daiichi Sankyo and AstraZeneca in June 2022 shows a vial and packaging for their Enhertu, an antibody-chemotherapy drug administered intravenously.
Until now, breast cancers have been categorized as either HER2-positive — the cancer cells have more of the protein than normal — or HER2-negative. Doctors reporting the advance Sunday said it will make “HER2-low” a new category for guiding breast cancer treatment. In the new study, the drug lengthened the time patients lived without their cancer progressing and improved survival compared with patients given standard chemotherapy.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Drug could help thousands with advanced breast cancer, researchers sayThe latest gain for targeted cancer therapy could open new treatment possibilities to thousands of patients with advanced breast cancer.
Weiterlesen »
Researchers: Breast cancer drug could help more patientsDoctors are reporting a new gain in breast cancer treatment.
Weiterlesen »
Drug could help thousands with advanced breast cancer, researchers sayThe latest gain for targeted cancer therapy could open new treatment possibilities to thousands of patients with advanced breast cancer.
Weiterlesen »
Researchers: Breast Cancer Drug Could Help More PatientsDoctors are reporting a new gain in breast cancer treatment. Some HER2 negative breast cancers are actually “HER2 low” and can benefit from a drug targeting the HER2 protein.
Weiterlesen »
New gallery exhibition explores postpartum with AI and synthetic breast milkScience-influenced artist Ani Liu became a parent shortly before the pandemic, and she channeled that experience into a new show called “Ecologies of Care.”
Weiterlesen »
Breast-Feeding the MicrobiomeWhy human breast milk is a scientific marvel.
Weiterlesen »